PharmaVoice Mar 10, 2026 Executives want in, but researchers want out — how pharma’s US job picture is changing
PharmaVoice Mar 9, 2026 The first KRAS drugs have been sluggish on the market. Will the next generation fare better?
PharmaVoice Mar 3, 2026 J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks